About Us

Who We Are

Oncostrata is a clinical science and data management consultancy in oncology and hematology. We provide dedicated support to new and established biotechs and pharma, tailoring our services to the clinical development program needs of each client.

From intelligent study start up and medical data review, ensuring data quality and integrity from the trial beginning, to key clinical documentation for health authority submissions and filing, we can help your study have the best chance for success.

Our PhD- and MD-level scientists bring expertise spanning a variety of mechanisms of action including small molecule inhibitors, immunotherapies, and cell-based therapies. We have decades of experience working on cancer clinical trials for clients across the pharmaceutical and biotech industry, clinical research networks, and academia.

Our Team

Joanna Hanks, MSc, PhD
Founder and Head of Clinical Science

During two decades working in oncology on sponsor and investigator-initiated studies for a range of Pharma and Biotech companies, Joanna has come to understand the significant challenges faced by Clinical Leads seeking scientific support for their studies. She founded Oncostrata with a mission to grow a permanent team of global clinical development experts, leveraging their expertise to provide exemplary scientific support to Sponsors at key stages in their trials.

At NIHR, Joanna collaborated with site investigators, recruiting patients, managing biomarkers and collecting data for several oncology trials, which led her to pursue a PhD comprising two large academic studies investigating DNA methylation and uracil misincorporation in colorectal cancer - this formed her PhD thesis and post doc which prepared her for the scientific rigor of clinical development.

Indication and Therapy Expertise
Oncology (lung, colorectal, prostate)
Small molecules, immuno-oncology
Phase I-III, post-marketing

Areas of Interest
Preventative care for colorectal cancer
Lung cancer immunotherapy
Patient reported outcomes
Post cancer treatment mental health care

Ana Metelo, MSc, PhD
Director, Clinical Science

  • Hematology (lymphoma, multiple myeloma, leukemia)
    Oncology (CNS tumors, Renal Cell Carcinoma)
    Small molecules, immuno-oncology, CAR T cell therapies
    Translational, Phase I-III

  • Innovative cell therapies & CAR T cells
    Early detection in hematology
    Genomic tools for personalized medicine
    Medical education & peer mentorship

Dildar Hassan, BDS, MSc
Clinical Scientist & Data Manager

  • Oncology (lung, colorectal, prostate, gastric cancer)
    Hematology (leukemia)
    Small molecule inhibitors, immune modulating antibodies, proteosome inhibitors
    Phase I-III, post-marketing

  • Data management & visualization tools
    Emerging clinical trial technologies (AI, database tools)
    Biomarkers in cancer therapy
    Peer mentorship

Chinnu Kurian, PharmD
Medical Data Reviewer

  • Oncology (lung, breast)
    Hematology (leukemia, lymphoma, multiple myeloma)
    Bispecific T cell engagers, immuno-oncology
    Phase I-III

  • Patient reported outcomes
    Causality assessments
    Signal detection & risk management
    Emerging clinical trial technologies (AI, database tools)

Snehal Shet, BAMS, PGDACR
Safety Scientist

  • Oncology (lung, colorectal, melanoma)
    Hematology (leukemia, lymphoma)
    Bispecific T cell engagers, small molecule inhibitors, biologic therapies
    Phase I-III, post-marketing

  • Signal detection & risk management
    Aggregate safety reports (DSUR, PBRER, PSUR)
    Causality assessments
    Regulatory submission

Jennifer Martin, MSc, DPhil
Clinical Scientist

  • Oncology (pediatric, lung)
    Small molecule targeted therapies, immuno-oncology
    Preclinical, Phase I-II

  • DNA damage response pathways
    Translational evidence for clinical trials
    Early detection methodologies
    Dose escalation designs

Chimi Handique, MBBS, MD
Clinical Scientist

  • Oncology (lung)
    Hematology (leukemia)
    Bispecific T cell engagers, small molecule inhibitors
    Phase I-III, post-marketing

  • Pharmacovigilance & regulatory submissions
    Regulatory & clinical writing
    Medical education, mentorships & trainings
    Emerging clinical trial technologies (AI, database tools)

Mafalda Dias, MSc, PhD
Clinical Science Associate

  • Oncology (lung, breast, melanoma, osteosarcoma)
    Oncolytic virus, multi-specific antibodies, vaccines, CAR T therapies
    Preclinical and drug development

  • Immuno-oncology
    Biotherapeutics for cancer treatment
    Clinical landscaping
    Business intelligence for strategic decision-making

Soumya Kumari, BAMS, MSc
Clinical Science Associate

  • Oncology (lung)
    Hematology (leukemia, multiple myeloma)
    Small molecule inhibitors, proteosome inhibitors
    Phase III, post-marketing

  • Cancer immunotherapy
    Quality of life & cancer care
    Emerging clinical trial technologies (AI, database tools)
    Innovative cell-based therapies

Our oncology experience is evident in everything we do.

Clients Who Trust Us